Gufic Biosciences Share Price
443.00+3.65 (+0.83%)
+22.14% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | - | 15% |
| - | - | - | -8% |
| 27% | 18% | 11% | 21% |
| 13% | 13% | 13% | 10% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
LUPIN
MANKIND
DRREDDY
AUROPHARMA
GUFICBIO
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,899.4 | ₹456833 Cr | 37.77 | 12.07 | 62.82 | ₹11479 Cr |
| 9,135 | ₹245426 Cr | 83.91 | 34.04 | 128.41 | ₹2568 Cr |
| 4,839 | ₹187320 Cr | 85.89 | 16.72 | 97.06 | ₹2163 Cr |
| 1,130 | ₹113217 Cr | 25.09 | 9.42 | 62.53 | ₹5040 Cr |
| 1,380.1 | ₹112212 Cr | 33.29 | 9.77 | 57.87 | ₹3879 Cr |
| 1,843.4 | ₹101155 Cr | 92.52 | 6.8 | 29.25 | ₹889 Cr |
| 2,109.2 | ₹97626 Cr | 17.66 | 30.95 | 154.36 | ₹5333 Cr |
| 2,330.9 | ₹96859 Cr | 47.42 | 13.75 | 71.08 | ₹1913 Cr |
| 1,157.7 | ₹96406 Cr | 29.92 | 5.32 | 63.99 | ₹4196 Cr |
| 1,652.3 | ₹93614 Cr | 25.22 | 17.95 | 96.84 | ₹3505 Cr |
| 443 | ₹4415 Cr | 60.1 | 2.23 | 10.4 | ₹64 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹261 Cr | ₹252 Cr | ₹231 Cr | ₹237 Cr | ₹224 Cr | ₹205 Cr | ₹208 Cr | ₹204 Cr | ₹203 Cr | ₹195 Cr | ₹202 Cr | ₹215 Cr |
| ₹46 L | -₹1 Cr | ₹79 L | ₹2 Cr | ₹93 L | ₹39 L | ₹2 Cr | ₹11 L | ₹1 Cr | ₹88 L | ₹42 L | ₹33 L |
| ₹261 Cr | ₹251 Cr | ₹232 Cr | ₹239 Cr | ₹225 Cr | ₹205 Cr | ₹210 Cr | ₹204 Cr | ₹204 Cr | ₹196 Cr | ₹202 Cr | ₹215 Cr |
| ₹222 Cr | ₹212 Cr | ₹206 Cr | ₹207 Cr | ₹198 Cr | ₹186 Cr | ₹178 Cr | ₹170 Cr | ₹171 Cr | ₹165 Cr | ₹169 Cr | ₹180 Cr |
| ₹47 Cr | ₹46 Cr | ₹34 Cr | ₹40 Cr | ₹34 Cr | ₹27 Cr | ₹36 Cr | ₹39 Cr | ₹37 Cr | ₹35 Cr | ₹37 Cr | ₹40 Cr |
| ₹9 Cr | ₹9 Cr | ₹8 Cr | ₹10 Cr | ₹9 Cr | ₹8 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹3 Cr | ₹4 Cr |
| ₹30 Cr | ₹29 Cr | ₹18 Cr | ₹23 Cr | ₹17 Cr | ₹11 Cr | ₹26 Cr | ₹29 Cr | ₹28 Cr | ₹27 Cr | ₹30 Cr | ₹31 Cr |
| ₹22 Cr | ₹22 Cr | ₹12 Cr | ₹17 Cr | ₹13 Cr | ₹8 Cr | ₹19 Cr | ₹22 Cr | ₹21 Cr | ₹20 Cr | ₹22 Cr | ₹23 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|
| — | — | — |
| ₹10 Cr | ₹10 Cr | ₹10 Cr |
| ₹0 | ₹10 L | ₹0 |
| ₹655 Cr | ₹591 Cr | ₹523 Cr |
| ₹655 Cr | ₹591 Cr | ₹523 Cr |
| ₹665 Cr | ₹601 Cr | ₹533 Cr |
| ₹4 L | ₹0 | ₹0 |
| ₹105 Cr | ₹131 Cr | ₹154 Cr |
| ₹17 Cr | ₹8 Cr | ₹2 Cr |
| ₹20 Cr | ₹25 Cr | ₹17 Cr |
| ₹18 Cr | ₹17 Cr | ₹15 Cr |
| ₹160 Cr | ₹181 Cr | ₹188 Cr |
| — | — | — |
| ₹199 Cr | ₹159 Cr | ₹166 Cr |
| ₹58 Cr | ₹70 Cr | ₹56 Cr |
| ₹254 Cr | ₹154 Cr | ₹142 Cr |
| ₹6 Cr | ₹4 Cr | ₹7 Cr |
| ₹518 Cr | ₹388 Cr | ₹372 Cr |
| ₹1342 Cr | ₹1169 Cr | ₹1093 Cr |
| ₹12 Cr | ₹6 Cr | ₹7 Cr |
| ₹385 Cr | ₹310 Cr | ₹317 Cr |
| — | — | — |
| ₹630 Cr | ₹614 Cr | ₹246 Cr |
| ₹139 Cr | ₹108 Cr | ₹87 Cr |
| ₹491 Cr | ₹506 Cr | ₹159 Cr |
| ₹22 Cr | ₹22 Cr | ₹307 Cr |
| ₹2 Cr | ₹2 Cr | ₹2 Cr |
| ₹2 Cr | ₹2 Cr | ₹2 Cr |
| ₹24 Cr | ₹13 Cr | ₹23 Cr |
| ₹2 Cr | ₹2 Cr | ₹1 Cr |
| ₹540 Cr | ₹545 Cr | ₹492 Cr |
| — | — | — |
| ₹324 Cr | ₹217 Cr | ₹200 Cr |
| ₹297 Cr | ₹315 Cr | ₹330 Cr |
| ₹76 Cr | ₹29 Cr | ₹13 Cr |
| ₹2 Cr | ₹2 Cr | ₹4 Cr |
| ₹102 Cr | ₹63 Cr | ₹53 Cr |
| ₹802 Cr | ₹625 Cr | ₹600 Cr |
| ₹284 Cr | ₹237 Cr | ₹228 Cr |
| ₹1342 Cr | ₹1169 Cr | ₹1093 Cr |
| ₹66 | ₹60 | ₹53 |
| ₹66 | ₹60 | ₹53 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|
| ₹87 Cr | ₹94 Cr | ₹116 Cr |
| ₹65 Cr | ₹44 Cr | ₹34 Cr |
| -₹95 Cr | ₹7 Cr | -₹130 Cr |
| ₹57 Cr | ₹145 Cr | ₹20 Cr |
| ₹45 Cr | ₹123 Cr | -₹7 Cr |
| -₹31 Cr | -₹71 Cr | -₹102 Cr |
| ₹32 Cr | -₹37 Cr | ₹82 Cr |
| ₹46 Cr | ₹15 Cr | -₹27 Cr |
| ₹16 Cr | ₹1 Cr | ₹29 Cr |
| ₹62 Cr | ₹16 Cr | ₹1 Cr |
Fundamental Ratios
Consolidated
Standalone
No results found